Biomarkers – News and Features

Mirus Bio has received a two-year Phase II SBIR grant to develop its microRNA-labeling technology for clinical research and potential diagnostic applications.

The Companies will develop automated solution for whole blood sample RNA isolation, amplification and expression profiling on GeneChip® Microarrays.

The megNet® software can be applied in understanding complex relations in living organisms, and characterizing various diseases, such as cardiac diseases and diabetes.

Rosetta and NYU will develop tests for lung and mesothelioma cancers using Rosetta's technology for extracting microRNA from blood.

Results of two studies funded by Project A.L.S. demonstrate that embryonic stem cells may provide a new tool for studying disease mechanisms and for identifying drugs to slow ALS.

The expanded facilities in Spring House, Pa., will house drug-development research into biomarkers, structural biology and pharmacogenomics.

Findings highlight Millennium leadership in personalized medicine and could strengthen the role of VELCADE as foundation of therapy in broad range of multiple myeloma patients.

The new facility will focus on the development of the Company's technology platform based on metabolomic, bioinformatics and biospectroscopy sciences.

The Company has appointed senior pharmaceutical industry professionals to establish its own personalized medicines operations in US.

The findings presented at AACR annual meeting support one of three diagnostic programs that Ciphergen currently has under development for ovarian cancer.